Presenilin 1 Glu318Gly polymorphism: Interpret with caution

Archives of Neurology

Volumn 62, Issue 10, 2005, Pages 1624-1627

  Goldman, Jill S ^a,e   Johnson, Julene K ^a   McElligott, Karen ^b   Suchowersky, Oksana ^c   Miller, Bruce L ^a   Van Deerlin, Vivianna M ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALBERTA CHILDREN'S HOSPITAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; GLYCINE; PRESENILIN 1;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; FAMILY HISTORY; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; MALE; PEDIGREE; PERSONALITY DISORDER; PRESENILE DEMENTIA; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR;

ALZHEIMER DISEASE; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PEDIGREE; POLYMORPHISM, GENETIC; PRESENILIN-1; RISK FACTORS;

EID: 26444443521     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.62.10.1624     Document Type: Article

References (14)

1. Rogaeva EA, Fafel KC, Song YQ, et al. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology. 2001;57:621-625.
2. Cruts M, van Duijn CM, Backhovens H, et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet. 1998;7:43-51.
3. Taddei K, Fisher C, Laws SM, et al. Association between presenilin-1 Glu318Gly mutation and familial Alzheimer's disease in the Australian population. Mol Psychiatry. 2002;7:776-781.
4. Forsell C, Froelich S, Axelman K, et al. A novel pathogenic mutation (Leu262Phe) found in the presenilin 1 gene in early-onset Alzheimer's disease. Neurosci Lett. 1997;234:3-6.
5. Dermaut B, Cruts M, Slooter AJ, et al. The Glu318Gly substitution in presenilin 1 is not causally related to Alzheimer disease. Am J Hum Genet. 1999;64:290-292.
6. Reznik-Wolf H, Treves TA, Shabtai H, et al. Germline mutational analysis of presenilin 1 and APP genes in Jewish-Israeli individuals with familial or early-onset Alzheimer disease using denaturing gradient gel electrophoresis (DGGE). Eur J Hum Genet. 1998;6:176-180.
7. Helisalmi S, Hiltunen M, Mannermaa A, et al. Is the presenilin-1 E318G missense mutation a risk factor for Alzheimer's disease? Neurosci Lett. 2000;278:65-68.
8. Cruts M, Van Broeckhoven C. Presenilin mutations in Alzheimer's disease. Hum Mutat. 1998;11:183-190.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the mental state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
10. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
11. National Institute on Aging; Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18(suppl):S1-S2.
12. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-259.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
14. Tang-Wai D, Lewis P, Boeve B, et al. Familial frontotemporal dementia associated with a novel presenilin-1 mutation. Dement Geriatr Cogn Disord. 2002;14:13-21.